inVentiv Health enters agreement to acquire Kforce Clinical Research

inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has signed a definitive agreement to acquire Kforce Clinical Research, Inc. ("KCR"), a provider of functional outsourcing solutions to pharmaceutical, biotech and medical device companies, from Kforce Inc. for $50 million in cash. 

KCR will be combined with inVentiv's existing functional service provider (FSP) and staffing businesses within the Clinical segment, expanding inVentiv's position as a leader in functional outsourcing and CRO services. With more than 30 years of experience and a broad portfolio of partners worldwide, the combined organization will leverage inVentiv Health's global reach, enabling the company to meet clients' strategic resourcing needs in more than 40 countries around the world.

"With its strong clinical monitoring expertise, a customer-focused approach and an impressive portfolio of clients, Kforce Clinical Research is an attractive complement to inVentiv's existing services. This acquisition expands our capability across the continuum of FSP, staffing and CRO services, further enhancing our ability to deliver flexible, cost-effective solutions for our clients," said Paul Meister, CEO of inVentiv Health.

KCR's range of clinical services include: site management and monitoring, clinical project and program management, clinical programming and data management, biostatistical analysis and reporting, pharmacovigilance, medical writing, regulatory affairs, and quality assurance and training. inVentiv anticipates adjusted annualized revenue of approximately $70 million, which reflects the previously disclosed contract loss by KCR and anticipated wins and contract expansion. 

The transaction is expected to close at the end of March 2012.

inVentiv Health also announced today that the Federal Trade Commission has approved its acquisition of SDI Health promotional and medical audit businesses from IMS Health. inVentiv expects to close the transaction this week. The syndicated offerings of the acquired businesses will be combined with the market research capabilities of Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry. 

Source:

inVentiv Health, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates